Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Ps Multiple | 5.9x - 6.5x | 6.2x |
| Selected Fwd Ps Multiple | 5.0x - 5.5x | 5.3x |
| Fair Value | ﷼88.44 - ﷼97.75 | ﷼93.10 |
| Upside | 17.8% - 30.2% | 24.0% |
| Benchmarks | Ticker | Full Ticker |
|---|---|---|
| Al Hammadi Holding Company | 400,700.0% | SASE:4007 |
| Dr. Sulaiman Al Habib Medical Services Group Company | 401,300.0% | SASE:4013 |
| Middle East Healthcare Company | 400,900.0% | SASE:4009 |
| National Medical Care Company | 400,500.0% | SASE:4005 |
| Dr. Soliman Abdel Kader Fakeeh Hospital Company | 401,700.0% | SASE:4017 |
| Mouwasat Medical Services Company | 400,200.0% | SASE:4002 |
| Select Price / LTM Sales Ratio | ||||||||
| Benchmark Companies | ||||||||
| 4007 | 4013 | 4009 | 4005 | 4017 | 4002 | |||
| SASE:4007 | SASE:4013 | SASE:4009 | SASE:4005 | SASE:4017 | SASE:4002 | |||
| Historical Sales Growth | ||||||||
| 5Y CAGR | 3.4% | 17.4% | 14.0% | 12.8% | 11.2% | 9.2% | ||
| 3Y CAGR | 6.6% | 15.6% | 15.5% | 15.2% | 12.4% | 10.3% | ||
| Latest Twelve Months | 2.0% | 21.7% | 8.2% | 23.4% | 13.5% | 5.7% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 20.5% | 20.0% | 3.9% | 18.0% | 11.7% | 26.5% | ||
| Prior Fiscal Year | 25.8% | 21.5% | 0.6% | 22.3% | 12.0% | 24.3% | ||
| Latest Fiscal Year | 29.4% | 20.7% | 9.8% | 23.0% | 10.3% | 22.4% | ||
| Latest Twelve Months | 29.6% | 19.6% | 13.6% | 21.9% | 10.2% | 23.0% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 15.2x | 34.7x | 11.6x | 20.6x | 23.4x | 15.6x | ||
| Price / LTM Sales | 5.2x | 7.8x | 1.7x | 5.3x | 3.3x | 5.1x | ||
| LTM P/E Ratio | 17.4x | 39.9x | 12.7x | 24.2x | 32.5x | 22.3x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/S Ratio | 1.7x | 5.2x | 7.8x | |||||
| Historical LTM P/S Ratio | 5.9x | 8.2x | 9.4x | |||||
| Selected Price / Sales Multiple | 5.9x | 6.2x | 6.5x | |||||
| (x) LTM Sales | 2,921 | 2,921 | 2,921 | |||||
| (=) Equity Value | 17,107 | 18,007 | 18,908 | |||||
| (/) Shares Outstanding | 200.0 | 200.0 | 200.0 | |||||
| Implied Value Range | 85.53 | 90.04 | 94.54 | |||||
| FX Rate: SAR/SAR | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 85.53 | 90.04 | 94.54 | 75.10 | ||||
| Upside / (Downside) | 13.9% | 19.9% | 25.9% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | 4007 | 4013 | 4009 | 4005 | 4017 | 4002 | |
| Value of Common Equity | 6,072 | 92,820 | 5,062 | 7,302 | 9,315 | 15,020 | |
| (/) Shares Outstanding | 160.0 | 350.0 | 92.0 | 44.7 | 230.0 | 200.0 | |
| Implied Stock Price | 37.95 | 265.20 | 55.00 | 163.40 | 40.50 | 75.10 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 37.95 | 265.20 | 55.00 | 163.40 | 40.50 | 75.10 | |
| Trading Currency | SAR | SAR | SAR | SAR | SAR | SAR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |